Analyst R. Daniels lowers Astrana Health's FY2024 EPS estimate, while other analysts maintain buy ratings.
Analyst R. Daniels has lowered William Blair's FY2024 earnings per share (EPS) estimate for Astrana Health (NASDAQ: ASTH) from $1.39 to $1.18 per share. Despite this, other analysts including Baird R W, Stifel Nicolaus, Robert W. Baird, and Truist Financial have assigned buy or strong buy ratings to the company, which reported a Q3 earnings beat ($0.40 EPS vs estimated $0.39). With an average rating of "Buy" and an average target price of $55.75, Astrana Health operates as a physician-centric technology-powered healthcare management company with three segments: Care Partners, Care Delivery, and Care Enablement.
August 10, 2024
4 Articles